Answers are grounded in this paper and cite their sources.
Acetylsalicylic acid, more commonly known as aspirin, has been used in clinical practice for decades as analgesic, antipyretic and anti-inflammatory drug. In recent years, its potential in prevention and therapy of oncological diseases has become a new topic of research. The article summarizes modern data on molecular and cellular mechanisms underlying antitumor action of aspirin. The main targets of acetylsalicylic acid are cyclooxigenase-1 and cyclooxigenase-2, inhibition of which leads to a decrease in prostaglandin production and modulation of inflammatory response. Additionally, aspirin affects apoptosis, proliferation, angiogenesis, and metastasis of tumor cells. Cyclooxigenases-independent mechanisms are also considered including activation of AMP-dependent protein kinase (AMPK), inhibition of nuclear transcription factor κB (NF-κB) and RhoA/ROCK pathway; results of clinical trials investigating efficacy of aspirin in various malignant neoplasms including colorectal, breast and prostate cancers are presented. The review focuses on the necessity of further studies aimed at identification of predictive biomarkers and stratification of patients who can have the strongest response to therapy taking into account molecular and genetic profile of the tumors (for example, hyperexpression of cyclooxygenase-2 or alterations in the PI3K/AKT signaling pathway).
No takes yet. Share an insight, caveat, or question.
Kuznetsova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: